MYCN and neuroblastoma: Given the many examples of cancers dependent on oncogenic Wnt/β-catenin signaling (Clevers and Nusse, 2012), such as colorectal cancers which have activating mutations in β-catenin or loss of function APC mutations (Fodde and Tomlinson, 2010), and that MYCN is a target of Wnt signaling (ten Berge et al., 2008), it was reasonable to propose that Wnt/β-catenin signaling would represent an oncogenic pathway in NB.